Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has worked hard but unsuccessfully to create an one-time therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix.

In development of this treatment, CytoDyn has cast its net far and wide both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will actually be used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as a combination treatment in the curing of multi-drug-resistant HIV are actually closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of the last few shares of mine. My first CytoDyn article, “CytoDyn: What In order to Do When It is Too Good To Be True?”, set out the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan offered such a very promotional image in the Uptick Newswire employment interview which I came away with an inadequate impression of the company.

Irony of irony, the poor viewpoint of mine of the company has grown steadily, yet the disappointment has not been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger at the moment still disappoints? Therein lies the story; permit me to explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the therapy and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s payment of $3.5 million transfers ownership of the expertise as well as linked intellectual property from Progenics to CytoDyn, and also roughly 25 million mg of bulk drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 huge number of) and the first new drug application approval ($5 million), as well as royalty payments of five percent of net sales after commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to purchase a sector cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many indications and many therapies, it has this single treatments and a “broad pipeline of indications” because it places it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely advantageous therapy in dozens of indications.

The opening banner of its on the website of its (below) shows an active organization with diverse interests albeit focused on leronlimab, multiple disease sorts, multiple publications and multiple presentations.

Might all this be smoke cigarettes and mirrors? That is a question I have been asking myself with the really start of my interest in this business. Judging by way of the multiples of thousands of various comments on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this question.

CytoDyn is a classic battleground, or perhaps some could say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *